This Regulation lays down detailed procedural rules for joint clinical assessments of medical devices and in vitro diagnostic medical devices (‘medical devices’) at Union level, as regards:
cooperation of the Member State Coordination Group on Health Technology Assessment established under Article 3 of Regulation (EU) 2021/2282 (‘the Coordination Group’) and the Commission acting as secretariat of the Coordination Group (‘the HTA secretariat’) with the notified bodies designated in accordance with Regulation (EU) 2017/745 or Regulation (EU) 2017/746 (‘the notified bodies’) and with the expert panels designated in accordance with Article 106(1) of Regulation (EU) 2017/745 (‘the expert panels’) in the form of exchange of information as regards the preparation and update of joint clinical assessments;
interaction, including the timing thereof, with and between the Coordination Group, its subgroups and health technology developers, patients, clinical experts and other relevant experts (‘individual experts’) during joint clinical assessments and their updates;
general procedural rules on the selection and consultation of stakeholder organisations and individual experts in joint clinical assessments;
the format and templates for dossiers with information, data, analyses and other evidence to be provided by health technology developers for joint clinical assessments;
the format and templates for joint clinical assessment reports and summary reports.